Nabiximols
- Generic Name
- Nabiximols
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C42H60O4
- CAS Number
- 56575-23-6
- Unique Ingredient Identifier
- K4H93P747O
- Background
Nabiximols (tradename Sativex®) is a whole plant extract from the Cannabis species Cannabis sativa L. that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol). For trademark purposes, purified CBD is branded as Nabidiolex®, while THC is purified as the product Tetrabinex®. Sativex® is available in a 1:1 formu...
- Indication
In Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy.
...
- Associated Conditions
- -
- Associated Therapies
- -
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Michael, Levy M.D.,Ph.D.
- Target Recruit Count
- 44
- Registration Number
- NCT05974293
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 234
- Registration Number
- NCT05629702
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
🇬🇧Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT04984278
- Locations
- 🇨🇿
NeuropsychiatrieHK, Hradec Králové, Czechia
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Vithas Nisa Sevilla, Sevilla, Spain
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT04657666
- Locations
- 🇵🇱
Clinical Trial Site 2, Poznan, Wielkopolskie, Poland
🇵🇱Clinical Trial Site, Zabrze, Poland
🇵🇱Clinical Trial Site 3, Katowice, Slaskie, Poland
Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT04592159
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT04203498
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇵🇱Neurologiczny NZOZ Centrum Leczenia SM Ośrodek Badań Klinicznych im. dr n. med. Hanki Hertmanowskiej Witosław Cieślak, Plewiska, Poland
🇺🇸Neurostudies - Port Charlotte, Port Charlotte, Florida, United States
CANNAbinoids in the Treatment of TICS (CANNA-TICS)
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 98
- Registration Number
- NCT03087201
- Locations
- 🇩🇪
University of Freiburg, Psychiatry and Psychotherapy, Freiburg, Germany
🇩🇪Uniklinik RWTH Aachen, Psychiatry and Psychotherapy, Aachen, Germany
🇩🇪University Hospital Cologne, Psychiatry and Psychotherapy, Cologne, Germany
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 406
- Registration Number
- NCT01424566
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 399
- Registration Number
- NCT01361607
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 660
- Registration Number
- NCT01337089
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.